Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 30Plasma cell 26Other hematologic neoplasm 9Myeloid 5Sarcoma 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 315Radiotherapy 139Cetuximab 133pembrolizumab 131Docetaxel 122Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 29apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × plerixafor × Head & Neck × Clear all
NCT04058145 2020-09-07

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡